Investigation of bluebird bio, inc. Announced
Pomerantz LLP has initiated an inquiry on behalf of investors of bluebird bio, inc. (NASDAQ: BLUE). This investigation seeks to determine if the company and its officials have been involved in any fraudulent practices related to securities or engaged in other unlawful business activities.
Acquisition Deal Announced
Recently, bluebird bio communicated that it has signed an agreement for acquisition by leading global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, alongside experienced biotech executives. This deal promises bluebird shareholders a cash payment of $3.00 for each share they own, along with a contingent payment that may total $6.84 if certain product sales goals are met. If bluebird achieves $600 million in net sales within a specified period, there is a possibility of a total compensation reaching up to $9.84 per share.
Transaction Details
The announcement highlighted that this transaction is viewed as the only viable option to provide value to shareholders, especially after repeated setbacks with the FDA regarding priority review vouchers. These setbacks put bluebird’s existing operations at risk, which has prompted concerns over potential defaults on their debt obligations.
Market Reaction to the News
In light of the acquisition announcement, bluebird's stock witnessed a drastic downturn. The share price fell significantly, closing down by 42.05% to end the trading day at $4.08 per share. This reaction from the market indicates investors' concerns regarding the future of bluebird amidst ongoing challenges.
Pomerantz LLP's Role
With a rich history and widespread recognition, Pomerantz LLP is noted for its commitment to tackling issues related to corporate misconduct, securities fraud, and breaches of fiduciary duty. Founded by legal pioneer Abraham L. Pomerantz, the firm has been at the forefront of securities class action litigation for over 85 years. It possesses an established track record of securing substantial financial recoveries on behalf of affected investors.
Promoting Shareholder Rights
Each investment decision carries its own risks, and it’s crucial for bluebird bio shareholders to evaluate the implications of the ongoing investigation. Pomerantz LLP is dedicated to advocating for the rights of investors, ensuring they are informed about their options and potential actions in light of the current developments.
Contact Information
The law firm encourages any bluebird bio investors who may have been affected to contact Danielle Peyton for further information. The firm is here to guide affected shareholders through this challenging period and address any concerns they may have regarding their investments.
Frequently Asked Questions
What is the aim of the investigation by Pomerantz LLP?
The investigation seeks to determine whether bluebird bio and its officers engaged in securities fraud or unlawful business practices.
What does the acquisition deal entail for bluebird bio shareholders?
Shareholders may receive $3.00 in cash for each share, plus potential contingent payments of $6.84 if specific sales targets are met.
How did the market react to the acquisition announcement?
Following the announcement, bluebird's stock price fell by 42.05%, reflecting significant investor concerns.
Who can shareholders contact if they have questions?
Shareholders can reach out to Danielle Peyton at Pomerantz LLP for more information and assistance.
What is Pomerantz LLP known for?
Pomerantz LLP is recognized for its long-standing commitment to protecting the rights of investors and has a notable history in handling corporate and securities litigation.
